G004366

HPLC Analysis of Verapamil and Metabolites in Rat Plasma on Ascentis^® Express C18 after Phospholipid Removal using HybridSPE^®-Phospholipid

application for SPE, application for LC-MS

Eigenschaften

• Methode(n): LC/MS: suitable; solid phase extraction (SPE): suitable
• Testparameter: SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U); sample preparation: SPE (Solid Phase Extraction); column: Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U); sample/matrix: Rat plasma spiked with verapamil and metabolites at 10 ng/mL; mobile phase: [A] water; [B] acetonitrile, pH 2.55 adjust with formic acid (30:70, A:B); flow rate: 0.6 mL/min; column temp.: 35 °C; detector: TOF/MS; injection: 1 μL; sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile; elution: apply vacuum
• Eignung: application for LC-MS; application for SPE
• Anwendung(en): clinical

Beschreibung

Rechtliche Hinweise

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany